INTRODUCTION: Nonmedical use of prescription opioid analgesics is associated with epidemic levels of morbidity and mortality. There are several factors that affect the abuse liability of the various opioids, including likability or the pleasurable subjective effects. Due to rising public health concerns over escalating prescription opioid abuse, we sought to examine the literature about abuse liability with a specific focus on likability studies. METHODS: A search of EMBASE and MEDLINE databases identified articles that described the comparative likeability and/or abuse potential of hydrocodone and oxycodone relative to each other and/or of either one to morphine. After an assessment of study quality using the Oxford/Jadad scale, relevant details such as demographics, study design, and outcome measures were compiled into an evidence table. RESULTS: We identified nine studies that met inclusion criteria. All were double-blinded, randomized, placebo-controlled crossover studies and scored 5 out of 5 Jadad scale. There was no consistent clinically significant difference between abuse liability of morphine and hydrocodone. Oxycodone demonstrated high abuse liability on the basis of its high likability scores and a relative lack of negative subjective effects. CONCLUSION: Oral oxycodone has an elevated abuse liability profile compared to oral morphine and hydrocodone.
INTRODUCTION: Nonmedical use of prescription opioid analgesics is associated with epidemic levels of morbidity and mortality. There are several factors that affect the abuse liability of the various opioids, including likability or the pleasurable subjective effects. Due to rising public health concerns over escalating prescription opioid abuse, we sought to examine the literature about abuse liability with a specific focus on likability studies. METHODS: A search of EMBASE and MEDLINE databases identified articles that described the comparative likeability and/or abuse potential of hydrocodone and oxycodone relative to each other and/or of either one to morphine. After an assessment of study quality using the Oxford/Jadad scale, relevant details such as demographics, study design, and outcome measures were compiled into an evidence table. RESULTS: We identified nine studies that met inclusion criteria. All were double-blinded, randomized, placebo-controlled crossover studies and scored 5 out of 5 Jadad scale. There was no consistent clinically significant difference between abuse liability of morphine and hydrocodone. Oxycodone demonstrated high abuse liability on the basis of its high likability scores and a relative lack of negative subjective effects. CONCLUSION: Oral oxycodone has an elevated abuse liability profile compared to oral morphine and hydrocodone.
Authors: William W Stoops; Kevin W Hatton; Michelle R Lofwall; Paul A Nuzzo; Sharon L Walsh Journal: Psychopharmacology (Berl) Date: 2010-07-28 Impact factor: 4.530
Authors: Sandra D Comer; Maria A Sullivan; Robert A Whittington; Suzanne K Vosburg; William J Kowalczyk Journal: Neuropsychopharmacology Date: 2007-06-20 Impact factor: 7.853
Authors: Stephen Bruehl; John W Burns; Steven D Passik; Rajnish Gupta; Asokumar Buvanendran; Melissa Chont; Erik Schuster; Daria Orlowska; Christopher R France Journal: J Pain Date: 2015-04-16 Impact factor: 5.820
Authors: Scott G Weiner; Shih-Chuan Chou; Cindy Y Chang; Chad Garner; Sanae El Ibrahimi; Sara Hallvik; Michelle Hendricks; Olesya Baker Journal: Pain Med Date: 2020-12-25 Impact factor: 3.750